Innovative Diabetes Therapies and Impact on Peripheral and Autonomic Diabetic Neuropathies: A State-of-the-Art Review.
This state-of-the-art narrative review examines the potential role of innovative diabetes therapies — specifically incretin-based therapies (GLP-1 receptor agonists), SGLT2 inhibitors, and emerging dual/triple receptor agonists — in modifying the course of diabetic peripheral neuropathy (DPN) and autonomic diabetic neuropathy. The authors synthesize evidence from preclinical models, clinical trials, and real-world observational studies, arguing that GLP-1 RAs and SGLT2 inhibitors may offer neuroprotective benefits beyond their established glucose-lowering effects, potentially through attenuation of inflammation and oxidative stress, improved mitochondrial function, and reduced neuronal damage. The review also highlights novel dual and triple receptor agonists as emerging agents with theoretical synergistic neuroprotective potential via simultaneous activation of multiple metabolic pathways. Limitations inherent to this paper include its narrative (non-systematic) design, which introduces selection bias, and the authors' own acknowledgment that clinical data on newer agents in the context of DN remain limited. The review does not generate new primary data. Overall, it provides a useful conceptual synthesis of an evolving therapeutic landscape but cannot establish causality or definitive efficacy for any agent in DN.
Why this grade: This is a narrative review that synthesizes existing preclinical and clinical literature without conducting original data collection or meta-analysis, precluding independent evidence grading beyond its source materials.
As a leading complication of diabetes mellitus, diabetic neuropathy (DN) represents a major public health challenge due to its high prevalence and impact on patients' quality of life. The most common form, diabetic peripheral neuropathy (DPN), is characterized by progressive sensory loss, neuropathic pain, and autonomic dysfunction, all of which can significantly increase the risk of serious complications, such as foot ulcers and amputations. Traditionally, therapeutic strategies for DN have been largely limited to symptomatic management. However, recent advancements in diabetes therapy have opened promising avenues for disease-modifying interventions. In particular, incretin-based therapies and sodium-glucose co-transporter 2 (SGLT2) inhibitors have attracted increasing interest not only for their glucose-lowering effects, but also for their broader metabolic, renal, and cardiovascular benefits. In this narrative review, we synthesize emerging evidence on the potential role of these innovative therapies in the management of DN. Preclinical models, clinical trials and real-world observational studies strongly support the hypothesis that glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and SGLT2 inhibitors may confer neuroprotective benefits. Beyond these established classes, novel agents such as dual and triple receptor agonists are currently being investigated. Although clinical data on their effects in DN are still limited, the simultaneous activation of multiple metabolic pathways suggests the potential for synergistic neuroprotective effects through enhanced regulation of glucose and lipid metabolism, attenuation of systemic inflammation and oxidative stress, improvement of mitochondrial function and reduction of neuronal damage. Although innovative diabetes therapies are still in early stages of development, they reflect a rapidly evolving landscape in the management of DN in the future.
Educational summary of published research — not medical advice. License: cc by-nc. Full text is shown only where licensing permits.